CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Inclusion Criteria: * DONOR: Ability to comprehend the investigational nature of the study and provide informed consent * DONOR: Willing to receive Triplex vaccination, a minimum of 14 days prior to the PBSC collection * DONOR VACCINATION: Donors are eligible to be vaccinated prior to the determination of their human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human T-cell lymphotropic virus (HTLV) status. The exclusion criteria for transplant is independent of eligibility for vaccination and is determined by the exclusion criteria for transplant from donors * RECIPIENT: All subjects must have the ability to understand and the willingness to sign a written informed consent * RECIPIENT: Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT * RECIPIENT: Age 18 to 75 years * RECIPIENT: Planned HCT for the treatment of the following hematologic malignancies: lymphoma (Hodgkin and non-Hodgkin), myelodysplastic syndrome, acute lymphoblastic leukemia in first or second remission, acute myeloid leukemia in first or second remission, chronic myelogenous leukemia (in first chronic or accelerated phase, or in second chronic phase), chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis (City of Hope \[COH\] only). Patients with multiple myeloma are excluded * RECIPIENT: CMV seropositive * RECIPIENT: Planned related HCT with 8/8 (A, B, C, DRB1) …